Amikacin sulfate is an intravenous drug used for the short-term treatment of a variety of bacterial infections. The presence of glass particulate in the drug could result in irritation, swelling and blood clots.
The recalled lots were distributed to wholesalers, retailers and pharmacies across the country. Teva issued an Urgent Drug Recall Letter to customers, urging them to stop use or distribution and quarantine the product immediately.
So far, Israel-based Teva has not received any reports of adverse events or complaints over the recall.
More articles on supply chain:
Express Scripps adds new drugs to its exclusion list
Teva must divest 79 generics to acquire Allergan’s generic pharma for $40.5 billion
America’s Essential Hospitals partners with Premier to improve supply chain management
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
